Related Experiment Video
Updated: Aug 13, 2026

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Published on: November 18, 2013
A novel missense mutation C127R (FH Zagreb) in the LDL-receptor gene
A S Rukavina1, R Z Topić, G Ferencak
1Clinical Institute of Laboratory Diagnosis, Zagreb University School of Medicine and Clinical Hospital Center, Croatia. ana.stavljenic-rukavina@zg.tel.hr
Insights
Researchers identified two mutations, C127R and D200G, in the low-density lipoprotein receptor gene linked to familial hypercholesterolemia. The novel C127R mutation was found in Croatian patients, contributing to genetic understanding of the disease.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Disease
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low-density lipoprotein (LDL) cholesterol.
- Mutations in the LDL receptor (LDLR) gene are a primary cause of FH.
- Identifying specific mutations is crucial for genetic diagnosis and understanding disease prevalence.
Purpose of the Study:
- To identify novel mutations in the LDLR gene responsible for familial hypercholesterolemia.
- To characterize the prevalence of specific LDLR mutations in a Croatian FH population.
Main Methods:
- Single-strand conformation polymorphism (SSCP) analysis was used to screen for mutations in exon 4 of the LDLR gene.
- DNA sequencing was employed to confirm and characterize identified mutations.
- Restriction endonuclease analysis (Dsa I) was used to validate the novel C127R mutation.
Main Results:
- Two mutations, C127R (FH Zagreb) and D200G (FH Padova), were identified in exon 4 of the LDLR gene.
- The C127R mutation, a novel T-to-C substitution at nucleotide 442, results in an amino acid change from Cysteine to Arginine at codon 127.
- The D200G mutation, an A-to-G substitution at nucleotide 662, changes Aspartic acid to Glycine at codon 200.
- These two mutations account for approximately 0.7% of FH cases in the screened Croatian population.
Conclusions:
- A novel mutation, C127R, in the LDLR gene causing familial hypercholesterolemia has been identified and characterized.
- The identified mutations, C127R and D200G, contribute to the genetic landscape of familial hypercholesterolemia in Croatia.
- This study highlights the importance of mutation screening for understanding FH etiology and epidemiology.
Abstract:
We employed the analysis of single-strand conformation polymorphisms to identify mutations in exon 4 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. Three familial hypercholesterolemia heterozygotes had abnormal single-strand conformation polymorphism patterns. DNA sequencing revealed that the abnormal pattern of exon 4A was due to heterozygosity (T/C) at nucleotide 442. Nucleotide 442 is the first base of codon 127, and the T-->C mutation (C127R) changes this codon from CysTGT to ArgCGT. Abnormal patterns of exon 4B were due to heterozygosity (A/G) at nucleotide 662: nucleotide 662 is the second base of codon 200, and the A-->G mutation (D200G) changes this codon from AspGAC to GlyGGC. Mutation D200G was previously described as FH Padova, but mutation C127R (FH Zagreb) has not been reported previously. This novel mutation was confirmed by restriction endonuclease analysis with Dsa I. The screening of 420 familial hypercholesterolemia heterozygotes suggests that C127R and D200G account for about 0.7% of mutations causing familial hypercholesterolemia in Croatia.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Related Concept Videos
Mutations
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Pharmacogenomics: Identification of New Drug Targets
Lipid Catabolism
Point and Frameshift Mutations